Bevacizumab (Avastin) in treatment of maculopathy secondary to proliferative diabetic retinopathy (PDR) in Afghanistan
Archives of Clinical and Experimental Ophthalmology · 2023
DOI: 10.46439/ophthalmology.5.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical and Experimental Ophthalmology, 2023. Verfasst von Mohammad Delsoz und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
To investigate the efficacy of intravitreal anti-VEGF thera - py in the treatment of maculopathy secondary to Proliferative Diabetic Retinopathy (PDR) in Afghanistan.
Methods
A retrospective analysis was conducted of all PDR cases that underwent intravitreal anti-VEGF injection at the four leading hos - pitals in Kabul. The main outcome measures were visual acuity, and central retinal thickness as determined by optical coherence tomogra - phy. Information was also collected on the distance travelled by each patient and frequency of injections.
Result
This is a clinical study which assessed the safety and efficacy of Bevacizumab (Avastin), manufactured by Genentech, in the treat - ment of maculopathy secondary to Proliferative Diabetic Retinopathy (PDR). All of the patients suffered from Type II Diabetes Mellitus. A total of 174 (97 male, 77 female) patients (308 study eyes in total) took part in the clinical study with an average age of 57 years (range 27-80 years). 56 patients (32%) in the study were insulin dependent diabetics. Bevacizumab was given to patients by monthly intra-vitreal injections at
Zitieren
APA
Delsoz, M., Mousavi, S. H., & Hollands, P. (2023). Bevacizumab (Avastin) in treatment of maculopathy secondary to proliferative diabetic retinopathy (PDR) in Afghanistan. Archives of Clinical and Experimental Ophthalmology. https://doi.org/10.46439/ophthalmology.5.031
Vancouver
Delsoz M, Mousavi SH, Hollands P. Bevacizumab (Avastin) in treatment of maculopathy secondary to proliferative diabetic retinopathy (PDR) in Afghanistan. Archives of Clinical and Experimental Ophthalmology. 2023. doi:10.46439/ophthalmology.5.031
BibTeX
@article{Delsoz2023,
author = {Delsoz, Mohammad and Mousavi, Sayed Hamid and Hollands, P.},
title = {Bevacizumab (Avastin) in treatment of maculopathy secondary to proliferative diabetic retinopathy (PDR) in Afghanistan},
journal = {Archives of Clinical and Experimental Ophthalmology},
year = {2023},
doi = {10.46439/ophthalmology.5.031}
}
EUVIMED